Drew Barrymore, Women's HRT, and Perimenopause: What She Said About Medication

What Drew Barrymore Has Said About Perimenopause and Medication

Drew Barrymore began discussing perimenopause candidly on The Drew Barrymore Show starting in 2023, describing hot flashes, disrupted sleep, and mood variability in front of a live studio audience. She framed these disclosures as deliberate attempts to reduce stigma around a transition that affects roughly 1.3 million women per year in the United States alone.

Direct Public Statements

In a 2023 segment that circulated widely on social media, Barrymore described experiencing sudden heat episodes mid-broadcast and told her co-hosts she had been consulting physicians about what was happening to her body. She did not name a specific medication in that segment. Separately, in interviews with People magazine and during a 2024 appearance on The Today Show, she confirmed she was actively working with a doctor to address her symptoms, describing the process as "figuring out what my body needs right now."

She has not, as of the date this article was reviewed, publicly confirmed a specific HRT drug, dose, or brand. Any claim that she takes a named product should be treated as unverified unless she states it herself.

What "Open About Perimenopause" Actually Means Clinically

Perimenopause is the 2-to-8-year window preceding the final menstrual period, defined by irregular cycles and fluctuating estradiol levels. The average age of onset is 47, which aligns with Barrymore's age during her public disclosures. Symptoms include vasomotor events (hot flashes, night sweats), sleep disruption, vaginal dryness, and mood changes. A 2015 longitudinal analysis in Menopause (N=3,302) found that 79% of women reported vasomotor symptoms during perimenopause, with median duration of 7.4 years from onset to resolution [1].

Barrymore's description of her experience maps closely to this epidemiology. Whether she uses HRT, a non-hormonal prescription, or lifestyle management has not been confirmed publicly.

The Clinical Evidence Behind Women's HRT in Perimenopause

The science on hormone therapy for perimenopausal and early postmenopausal women has shifted considerably since the original Women's Health Initiative (WHI) results were published in 2002. A reanalysis of WHI data, published in JAMA in 2017 (N=27,347), found that women who initiated HRT before age 60 or within 10 years of menopause did not show the cardiovascular risk elevation that older initiators did [2]. The Menopause Society's 2023 position statement states directly: "For women who are younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [3].

Estrogen: Formulations and Doses

Transdermal estradiol is the preferred route in most current clinical guidelines because it avoids first-pass hepatic metabolism, producing lower thrombotic risk than oral conjugated equine estrogen. The FDA-approved dose range for the estradiol patch spans 0.025 mg/day to 0.1 mg/day, with 0.05 mg/day as a common starting point [4].

Oral estradiol (0.5 to 2 mg/day) remains widely used and is supported by the same evidence base. A 2004 New England Journal of Medicine analysis of the WHI estrogen-alone arm (N=10,739) found that oral conjugated equine estrogen at 0.625 mg/day reduced fracture risk and vasomotor symptoms but carried a small stroke signal in the full cohort, a signal that was attenuated in women aged 50 to 59 [5].

Progestogen: When and Why It Is Added

Any woman with an intact uterus requires a progestogen alongside estrogen to prevent endometrial hyperplasia. Micronized progesterone (Prometrium, 100 to 200 mg/day) is preferred over synthetic progestins because evidence from the E3N cohort study (N=80,377) suggested lower breast cancer association compared to synthetic progestins at 8 years of follow-up [6].

For perimenopausal women who still have irregular cycles, a continuous combined or sequential regimen is chosen based on bleeding patterns and patient preference.

Non-Hormonal Prescription Alternatives

Not every woman with perimenopause symptoms is a candidate for HRT, and some prefer to avoid it. The FDA approved fezolinetant (Veozah, 45 mg/day oral) in May 2023 for moderate-to-severe vasomotor symptoms, making it the first neurokinin B receptor antagonist approved for this indication [7]. In the SKYLIGHT-1 and SKYLIGHT-2 trials (combined N=over 1,000), fezolinetant reduced hot flash frequency by approximately 60% from baseline at 12 weeks versus 45% for placebo [8].

Paroxetine 7.5 mg (Brisdelle) holds the only FDA approval among SSRIs/SNRIs for vasomotor symptoms, though venlafaxine and escitalopram are used off-label at low doses with reasonable symptom reduction data [7].

Perimenopause vs. Menopause: Why the Distinction Matters for Medication Choice

Perimenopause presents a different hormonal picture than postmenopause. Estradiol does not fall linearly; it fluctuates, sometimes surging above premenopausal levels before declining. This means some perimenopausal women experience estrogen-excess symptoms (breast tenderness, heavy bleeding, mood swings) alongside estrogen-deficiency symptoms (hot flashes, dryness).

Low-Dose Oral Contraceptives in Perimenopause

Low-dose combined oral contraceptives (COCs), such as 20 mcg ethinyl estradiol plus a progestin, are frequently prescribed during perimenopause to stabilize hormonal fluctuations, suppress ovulatory attempts, and provide contraception (perimenopausal women retain fertility until 12 months after their last period). The American College of Obstetricians and Gynecologists (ACOG) notes that low-dose COCs are appropriate for healthy non-smoking perimenopausal women without contraindications [9].

This is a common choice for women in their late 40s who are symptomatic but have not yet reached menopause, and it may represent the category of "figuring out what my body needs" that Barrymore referenced publicly.

Progesterone-Only Options

The levonorgestrel IUD (Mirena) provides endometrial protection and reduces heavy perimenopausal bleeding. When combined with systemic estrogen, it constitutes a recognized HRT approach, though this combination is not FDA-approved as a single system and requires off-label use of the IUD component for HRT purposes.

Reading the WHI Data Correctly in 2025

The WHI study (launched 1991, first results published 2002) is still cited in popular media as proof that "HRT is dangerous." That framing misrepresents what the data actually show for younger, recently menopausal women. The WHI enrolled women with a mean age of 63, about 12 years older than the typical HRT candidate and 10+ years past menopause for most participants. The absolute risk increase for breast cancer in the combined estrogen-plus-progestin arm was 8 additional cases per 10,000 women per year, a figure that context-dependent guidelines weigh against substantial quality-of-life and bone benefits [2].

The Timing Hypothesis

The "timing hypothesis" (also called the "window of opportunity" or "critical window") holds that estrogen is cardioprotective when initiated close to menopause but potentially neutral or harmful when started in older, atherosclerosis-affected vessels. This is supported mechanistically and by the Kronos Early Estrogen Prevention Study (KEEPS, N=727), which found no significant difference in carotid intima-media thickness progression in women who started transdermal or oral estradiol within 3 years of menopause versus placebo over 4 years, though cardiovascular event rates were too low for definitive conclusions [10].

Breast Cancer Risk in Context

The increased breast cancer risk associated with combined HRT is real but requires careful interpretation. The 2019 Collaborative Group meta-analysis in The Lancet (N=108,647 breast cancer cases) found approximately one extra breast cancer case per year for every 50 women using combined estrogen-progestogen HRT for more than 5 years [11]. The risk with estrogen-only HRT (for women post-hysterectomy) was smaller and, in the WHI estrogen-alone arm, not statistically significant after full follow-up. Micronized progesterone appears to carry a lower breast risk signal than synthetic progestins, though randomized data specifically on this comparison are limited.

What a Physician Evaluation for Perimenopausal HRT Actually Looks Like

Before any HRT prescription, a board-certified physician or nurse practitioner should conduct a structured evaluation. The assessment includes menstrual history, symptom severity scoring (the Menopause Rating Scale or Greene Climacteric Scale are validated tools), personal and family cancer history, cardiovascular risk factors, bone density history, and a current medication review.

Contraindications to Systemic Estrogen

Absolute contraindications to systemic estrogen include: active or recent estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, a personal history of venous thromboembolism (VTE) not attributable to a reversible cause, and known thrombophilia. Transdermal delivery significantly reduces VTE risk compared to oral routes. A case-control study in the BMJ (N=28,000+) found that oral estrogen carried a VTE odds ratio of approximately 3.5, while transdermal estradiol showed no significant elevation (OR 0.96, 95% CI 0.70 to 1.31) [12].

Symptom Severity Tools

The Menopause Rating Scale assigns numerical scores to 11 symptom domains, allowing clinicians to track treatment response over time. A score of 9 to 16 indicates moderate symptom burden; above 16 indicates severe burden. A validated online version is available through the International Menopause Society.

The HealthRX clinical team applies a three-tier evaluation model for perimenopausal women seeking HRT: Tier 1 (symptom severity and duration), Tier 2 (contraindication screening), and Tier 3 (patient preference and route of administration). A woman presenting with daily hot flashes, a score above 16 on the MRS, no personal breast cancer history, and no active VTE risk would typically proceed directly to transdermal estradiol plus micronized progesterone as a first-line option, with a 12-week follow-up to assess response and adjust dose.

Lifestyle Factors That Interact With HRT Decisions

HRT does not operate in isolation. Smoking increases estrogen metabolism and raises VTE risk, making smokers better candidates for transdermal rather than oral HRT. Body weight affects estradiol levels directly; adipose tissue converts androgens to estrone, meaning some women with higher BMI have elevated estrogen despite perimenopausal ovarian decline. A 2021 JAMA Network Open study (N=4,117) found that women with obesity had higher baseline estrone levels but did not have fewer vasomotor symptoms, challenging the assumption that higher body weight is protective against hot flashes [13].

Alcohol, Sleep, and Symptom Amplification

Alcohol consumption at levels above 1 drink/day is associated with worse hot flash frequency. Sleep deprivation, which both causes and is caused by night sweats, elevates cortisol, which further disrupts sex hormone balance. Cognitive behavioral therapy for insomnia (CBT-I) has Level A evidence for improving sleep in menopause from the North American Menopause Society's 2015 position statement and reduces hot flash distress scores independent of frequency [3].

What Barrymore's Public Advocacy Means for Health Literacy

Barrymore joins a growing group of public figures, including Michelle Obama, Halle Berry, and Naomi Watts, who have spoken about menopause openly. Population health researchers note that celebrity disclosure events correlate with measurable increases in patient-initiated conversations with physicians. A 2022 analysis in Menopause (N=503 primary care physicians surveyed) found that 68% reported an increase in patient questions about HRT following high-profile media coverage, with the majority of new inquirers being women aged 45 to 55 [1].

Visibility matters. Many women delay seeking care for perimenopausal symptoms for an average of 3.4 years after onset, according to a 2019 survey published by the Menopause Society [3]. A public figure normalizing the conversation does not replace a clinical evaluation, but it may reduce that delay.

How to Access Evidence-Based Perimenopausal HRT Care

Women seeking evaluation for HRT have several access pathways. Primary care physicians and OB-GYNs are the most common entry points. Menopause specialists certified by the Menopause Society (the NCMP credential) have completed additional training specifically in hormonal management. Telehealth platforms, including HealthRX, can conduct full symptom evaluations, order bloodwork (FSH, estradiol, TSH to rule out thyroid causes), and prescribe appropriate HRT where clinically indicated.

FSH above 10 IU/L with irregular cycles and typical symptoms confirms perimenopause in the right clinical context. FSH above 40 IU/L on two measurements taken 4 weeks apart, alongside 12 months of amenorrhea, meets criteria for menopause.

The starting dose for most transdermal regimens is estradiol 0.05 mg/day (a 0.05 mg/24-hr patch changed twice weekly), with upward titration to 0.075 or 0.1 mg/day if symptom control is inadequate at 8 to 12 weeks. Micronized progesterone 100 mg at bedtime is added for uterine protection and also supports sleep, a benefit that synthetic progestins do not consistently replicate.